PPARA and metabolic dysfunction-associated steatohepatitis: Saroglitazar, a different dual PPARα/γ agonist, improved steatosis, lobular inflammation, hepatocellular ballooning, and fibrosis levels in an animal model of NASH 109 and it was found to ameliorate ALT, liver fat content, insulin resistance, and atherogenic dyslipidemia in NASH patients, along with positive histological indications110.